Case	Court	Filed	Status	Judge
Purdue Pharma L.P. et al v. Accord Healthcare Inc. 5:2024cv00284 4 patentsANDA 213564oxycodone hydrochloride	E.D.N.C.	2024-05-21	Active	—
Purdue Pharma L.P. et al v. Accord Healthcare Inc. 1:2022cv00913	D. Del.	2022-07-08	Terminated 2024-09-09	—
PURDUE PHARMA, LP et al v. Collegium Pharmaceutical, Inc. 1:2021cv10598	D. Mass.	2021-04-09	Terminated 2022-05-17	—
Purdue Pharma L.P. et al v. Accord Healthcare Inc. 1:2020cv01362 6 patentsANDA 213564oxycodone hydrochloride	D. Del.	2020-10-08	Terminated 2023-04-26	—
Purdue Pharma L.P. et al v. Intellipharmaceutics International Inc. et al 1:2020cv00515 2 patentsoxycodone hydrochloride	D. Del.	2020-04-15	Terminated 2020-07-28	—
Purdue Pharma L.P. et al v. Ascent Pharmaceuticals, Inc. 1:2018cv00855	D. Del.	2018-06-07	Terminated 2019-04-01	—
Purdue Pharma L.P. et al v. Intellipharmaceutics International Inc. et al 1:2018cv00404 10 patentsoxycodone hydrochloride	D. Del.	2018-03-14	Terminated 2020-07-28	—
Purdue Pharma L.P. et al v. Ascent Pharmaceuticals, Inc. 1:2018cv00083 7 patentsANDA 211178oxycodone hydrochloride	D. Del.	2018-01-11	Terminated 2019-04-01	—
Purdue Pharma L.P. et al v. Ascent Pharmaceuticals, Inc. 2:2018cv00196 7 patentsANDA 211178oxycodone hydrochloride	E.D.N.Y.	2018-01-11	Terminated 2018-02-27	—
Purdue Pharma L.P. et al v. Kashiv Pharma, LLC 1:2018cv00052 3 patentsANDA 203235oxycodone hydrochloride	D. Del.	2018-01-03	Terminated 2018-08-14	—
Purdue Pharma L.P. et al v. Amneal Pharmaceuticals, LLC 1:2018cv00051 20 patentsANDA 203235oxycodone hydrochloride	D. Del.	2018-01-03	Terminated 2018-08-14	—
Purdue Pharma L.P. et al v. Amneal Pharmaceuticals LLC 1:2017cv01421 3 patentsANDA 203235oxycodone hydrochloride	D. Del.	2017-10-10	Terminated 2018-08-14	—
Purdue Pharma L.P. et al v. Par Pharmaceutical, Inc. 1:2017cv01334	D. Del.	2017-09-20	Terminated 2017-10-12	—
Purdue Pharma L.P. et al v. Abhai, LLC et al 1:2017cv00450	D. Del.	2017-04-20	Terminated 2017-12-28	—
Purdue Pharma L.P. et al v. Intellipharmaceutics International Inc. et al 1:2017cv00392	D. Del.	2017-04-07	Terminated 2020-07-28	—
Purdue Pharma L.P. et al v. Amneal Pharmaceuticals, LLC 1:2017cv00210 3 patentsANDA 203235oxycodone hydrochloride	D. Del.	2017-03-01	Terminated 2018-08-14	—
Purdue Pharma L.P. et al v. Abhai, LLC et al 3:2016cv00058 11 patentsANDA 207493oxycodone hydrochloride	M.D. Fla.	2016-01-21	Terminated 2016-02-24	—
Purdue Pharma L.P. et al v. Abhai, LLC et al 1:2016cv00025 11 patentsANDA 207493oxycodone hydrochloride	D. Del.	2016-01-19	Terminated 2017-12-28	—
Purdue Pharma L.P. et al v. Collegium Pharmaceutical, Inc. 1:2015cv13783 1 patentoxycodone hydrochloride	D. Mass.	2015-11-06	Terminated 2022-05-17	—
Purdue Pharma L.P. et al v. Teva Pharmaceuticals USA, Inc. et al 1:2014cv02357 9 patentsANDA 202455oxycodone hydrochloride	S.D.N.Y.	2014-04-03	Terminated 2014-12-23	—
Purdue Pharma L.P. et al v. Teva Pharmaceuticals USA, Inc. 1:2013cv04606 2 patentsANDA 202455oxycodone hydrochloride	S.D.N.Y.	2013-07-02	Terminated 2014-12-23	—
Purdue Pharma L.P. et al v. PAR Pharmaceutical, Inc. 1:2013cv03374 2 patentsANDA 202434oxycodone hydrochloride	S.D.N.Y.	2013-05-17	Terminated 2013-09-24	—
Purdue Pharma L.P. et al v. Amneal Pharmaceuticals, LLC 1:2013cv03372 1 patentANDA 203235oxycodone hydrochloride	S.D.N.Y.	2013-05-17	Terminated 2015-04-09	—
Purdue Pharma L.P. et al v. Impax Laboratories, Inc. 1:2013cv03188 1 patentANDA 202483oxycodone hydrochloride	S.D.N.Y.	2013-05-10	Terminated 2013-12-06	—
Purdue Pharma L.P. et al v. Watson Laboratories, Inc. et al 1:2013cv00762 1 patentANDA 202352, 202372oxycodone hydrochloride extended release	S.D.N.Y.	2013-02-04	Terminated 2013-05-01	—
Purdue Pharma L.P. et al v. IMPAX Laboratories, Inc. 1:2013cv00763 2 patentsANDA 202483oxycodone hydrochloride	S.D.N.Y.	2013-02-01	Terminated 2013-12-06	—
Purdue Pharma L.P. et al v. Epic Pharma, LLC 1:2013cv00683 3 patentsANDA 204348oxycodone hydrochloride	S.D.N.Y.	2013-01-30	Terminated 2014-01-29	—
DEPOMED, INC. v. PURDUE PHARMA L.P. et al 3:2013cv00571 3 patentsoxycodone hydrochloride controlled-release	D.N.J.	2013-01-29	Terminated 2018-07-09	—
Purdue Pharma L.P. et al v. Watson Laboratories, Inc. 1:2012cv03111 1 patentANDA 202352oxycodone hydrochloride	S.D.N.Y.	2012-04-19	Terminated 2013-05-01	—
Purdue Pharma L.P. et al v. Mylan Pharmaceuticals Inc. et al 1:2012cv02959 3 patentsANDA 203915oxycodone hydrochloride	S.D.N.Y.	2012-04-13	Terminated 2014-01-29	—
Purdue Pharma L.P. et al v. Sandoz Inc. 1:2012cv00897 5 patentsANDA 202762oxycodone hydrochloride	S.D.N.Y.	2012-02-03	Terminated 2014-01-08	—
Purdue Pharma L.P. et al v. Amneal Pharmaceuticals, LLC 1:2011cv08153 4 patentsANDA 203235oxycodone hydrochloride	S.D.N.Y.	2011-11-10	Terminated 2014-01-29	—
Purdue Pharma L.P. et al v. Sandoz Inc. 1:2011cv04694 5 patentsANDA 202762oxycodone hydrochloride	S.D.N.Y.	2011-07-07	Terminated 2014-01-08	—
Purdue Pharma L.P. et al v. Ranbaxy Inc. et al 1:2011cv02401 3 patentsANDA 202427oxycodone hydrochloride	S.D.N.Y.	2011-04-08	Terminated 2013-04-30	—
Purdue Pharma L.P. et al v. IMPAX Laboratories, Inc. 1:2011cv02400 5 patentsANDA 202483oxycodone hydrochloride	S.D.N.Y.	2011-04-08	Terminated 2013-12-06	—
Purdue Pharma L.P. et al v. PAR Pharmaceutical, Inc. 1:2011cv02038 5 patentsANDA 202434oxycodone hydrochloride	S.D.N.Y.	2011-03-23	Terminated 2013-09-24	—
Purdue Pharma L.P. et al v. Teva Pharmaceuticals USA, Inc. 1:2011cv02037 4 patentsANDA 202455oxycodone hydrochloride	S.D.N.Y.	2011-03-23	Terminated 2014-01-14	—
Purdue Pharma L.P. et al v. Ranbaxy Inc. et al 1:2010cv03734 3 patentsANDA 78093, 200455, 200692oxycodone hydrochloride	S.D.N.Y.	2010-05-05	Terminated 2013-07-18	—

Source: PACER. NOS 835 (Patent - Abbreviated New Drug Application).

Citizen Petitions

26 petitions (3 open) from Regulations.gov

Petition	Type	Filed	Status	Petitioner
Citizen Petition from King & Spalding FDA-2000-P-0580 · 4 docket documents King & Spalding filed this citizen petition under section 505(j)(2)(C) of the Federal Food, Drug, and Cosmetic Act requesting that the FDA Commissioner declare that abbreviated new drug applications may be submitted for combination oxycodone hydrochloride/acetaminophen tablet products in four streng	Other	2018-08-16	Granted	King & Spalding
Citizen Petition from Pharmaceutical Manufacturing Research Services, Inc FDA-2018-P-2851 · 28 docket documents Pharmaceutical Manufacturing Research Services, Inc. filed this citizen petition on July 23, 2018, requesting that the FDA refrain from approving NDA No. 22324 for Remoxy ER, an opioid product submitted by Pain Therapeutics, Inc. under section 505(b), unless the applicant demonstrates substantial ev	505(q)	2018-07-24	Denied	Pharmaceutical Manufacturing Research Services, Inc
Citizen Petition from Hyman, Phelps & McNamara, PC on behalf of Collegium Pha... FDA-2018-P-1448 · 3 docket documents Hyman, Phelps & McNamara, PC, on behalf of Collegium Pharmaceutical, Inc., filed this citizen petition under section 505(q) of the Federal Food, Drug, and Cosmetic Act requesting that the FDA refuse to approve any pending NDA for extended-release oxycodone products, including Pain Therapeutics, Inc.	505(q)	2018-04-09	Open	Collegium Pharmaceutical, Inc
Citizen Petition from Lachman Consultant Services, Inc. FDA-2005-P-0009 · 7 docket documents Lachman Consultant Services, Inc. submitted this petition under Section 505(j)(2)(C) of the Federal Food, Drug, and Cosmetic Act requesting that the FDA determine that an Abbreviated New Drug Application may be submitted for Oxycodone Hydrochloride 7.5 mg Tablets, a new dosage strength based on the	Other	2018-01-10	Granted	Lachman Consultant Services, Inc.
Citizen Petition from King & Spalding FDA-1999-P-3513 · 5 docket documents King & Spalding filed this Section 505(j)(2)(C) citizen petition requesting that the FDA determine a liquid formulation containing 7.5 mg oxycodone hydrochloride and 500 mg acetaminophen per 15 mL is suitable for evaluation under an abbreviated new drug application (ANDA), based on the approved tabl	Other	2017-07-24	Denied	King & Spalding
Citizen Petition from Hyman, Phelps & McNamara, PC (Collegium Pharmaceutical,... FDA-2016-P-1946 · 6 docket documents Collegium Pharmaceutical, Inc., through counsel Hyman, Phelps & McNamara, P.C., filed this citizen petition under section 505(q) of the Federal Food, Drug, and Cosmetic Act requesting that the FDA refuse to approve any pending NDA or supplemental NDA for extended-release oxycodone drug products unle	505(q)	2016-07-08	Denied	Hyman, Phelps & McNamara, PC (Collegium Pharmaceutical, Inc. )
Citizen Petition from Purdue Pharma L.P. (Kleinfeld, Kaplan and Becker, LLP) FDA-2015-P-5108 · 16 docket documents Purdue Pharma L.P., through counsel, filed this citizen petition pursuant to 21 C.F.R. §§ 10.30, 314.50(i), 314.52, 314.54, and Section 505(b) of the Federal Food, Drug, and Cosmetic Act, requesting that FDA require Pfizer's 505(b)(2) NDA for AL0-02 (oxycodone extended-release tablets) to include ap	505(q)	2015-12-31	Denied	Purdue Pharma L.P. (Kleinfeld, Kaplan and Becker, LLP)
Citizen Petition from Kleinfeld Kaplan & Becker, LLP (KKB) FDA-2015-P-2120 · 10 docket documents Kleinfeld Kaplan & Becker, LLP, on behalf of Purdue Pharma L.P., filed this citizen petition under 21 C.F.R. sections 10.30, 314.50(i), 314.52, 314.54, and Section 505(b) of the Federal Food, Drug, and Cosmetic Act concerning Pfizer's Section 505(b)(2) NDA for AL0-02 (oxycodone extended-release). Pu	505(q)	2015-06-15	Denied	Kleinfeld Kaplan & Becker, LLP (KKB)
Citizen Petition From Purdue Pharma LP (Kleinfeld, Kaplan and Becker, LLP) FDA-2014-P-0205 · 4 docket documents Purdue Pharma LP filed this citizen petition requesting that the FDA exercise its authority under Section 505(o) of the Federal Food, Drug and Cosmetic Act to impose safety labeling changes on immediate-release opioid analgesics parallel to those mandated for extended-release and long-acting opioid	Other	2014-02-25	Partially Denied	Purdue Pharma LP (Kleinfeld, Kaplan and Becker, LLP)
Rhodes Technologies (Kleinfeld, Kaplan and Becker, LLP) - Citizen Petition FDA-2013-P-0425 · 3 docket documents Rhodes Technologies, through counsel, filed this citizen petition pursuant to sections 355 and 701 of the Federal Food, Drug, and Cosmetic Act requesting that the FDA maintain the current limit of not more than 10 parts per million of 14-hydroxycodeinone impurity in oxycodone hydrochloride active ph	Other	2013-05-01	Denied	—
Citizen Petition from Lachman Consultant Services, Inc. FDA-2001-P-0238 · 5 docket documents Lachman Consultant Services, Inc. filed this petition on behalf of a client requesting that the FDA determine whether Oxycontin (Oxycodone Hydrochloride) Extended-Release Tablets 160 mg, approved under NDA 20-553 and manufactured by Purdue Fredrick, Inc., was voluntarily withdrawn from marketing for	505(q)	2013-04-23	Denied	Lachman Consultant Services, Inc.
Lannett Company, Inc.- Citizen Petition FDA-2012-P-1180 · 4 docket documents Lannett Company, Inc. filed this petition under Section 505(j) of the Federal Food, Drug, and Cosmetic Act requesting that the FDA Commissioner determine that an Abbreviated New Drug Application for Oxycodone Hydrochloride Extended-Release Capsules may be submitted and considered bioequivalent to th	Other	2012-12-20	Open	—
Purdue Pharma L.P. (Kleinfeld, Kaplan and Becker LLP) - Citizen Petition FDA-2012-P-0939 · 6 docket documents Purdue Pharma L.P. filed this citizen petition pursuant to 21 C.F.R. §§ 10.30, 314.94, 314.127, and Section 505 of the Federal Food, Drug, and Cosmetic Act requesting that FDA require all abbreviated new drug applications citing the reformulated OxyContin (NDA # 22-272, oxycodone hydrochloride exten	505(q)	2012-10-24	Denied	—
Pfizer Inc. (Covington & Burling LLP) - Citizen Petition FDA-2012-P-1009 · 3 docket documents Pfizer Inc., as the successor in interest to King Pharmaceuticals and sponsor of the Oxecta (oxycodone hydrochloride) NDA 20-2080, filed this citizen petition on September 21, 2012, requesting that the FDA refrain from permitting abbreviated new drug applications to rely on Oxecta as a reference lis	505(q)	2012-09-25	Denied	—
Purdue Pharma L.P., (Kleinfeld, Kaplan and Becker, LLP) - Citizen Petition FDA-2012-P-0760 · 3 docket documents Purdue Pharma L.P. filed this citizen petition under 21 C.F.R. §§ 10.30, 314.94, 314.127, Part 320, and Section 505 of the FDCA regarding abbreviated new drug applications citing reformulated OxyContin (oxycodone hydrochloride extended-release) NDA #22-272 as the Reference Listed Drug. Purdue reques	505(q)	2012-08-16	Open	—
Lannett Company, Inc. and Cody Laboratories, Inc. (Alston & Bird LLP) - Citiz... FDA-2012-P-0189 · 6 docket documents Lannett Company Inc. and its subsidiary Cody Laboratories Inc. filed this citizen petition under Sections 201 and 505 of the Federal Food, Drug, and Cosmetic Act requesting that the FDA affirm the grandfather status of oxycodone hydrochloride (Lannett's Oxycodone Hydrochloride Oral Concentrate Solut	Other	2012-03-07	Denied	—
Varam, Inc. - Citizen Petition FDA-2011-P-0473 · 5 docket documents Varam, Inc. filed a citizen petition regarding OxyContin, requesting that the FDA consider the company's epidemiologic study program demonstrating the effectiveness of the reformulated OxyContin in deterring abuse, with the company presenting data on its abuse-deterrent reformulation that was approv	Other	2011-06-26	Denied	—
Purdue Pharma L.P. (Purdue) - Citizen petition FDA-2011-P-0045 · 6 docket documents Purdue Pharma L.P. filed this citizen petition on January 14, 2011, regarding King Pharmaceuticals' Section 505(b)(2) NDA for Remoxy (oxycodone controlled-release) Capsules, seeking to prevent approval until King includes appropriate patent certifications for the listed drug OxyContin (oxycodone hyd	505(q)	2011-02-08	Denied	—
Sheppard, Mullin, Richter & Hampton LLP - Citizen Petition FDA-2010-P-0540 · 13 docket documents Sheppard Mullin Richter & Hampton LLP, on behalf of Purdue Pharma LP, filed this citizen petition requesting that the FDA determine that oxycodone hydrochloride extended release tablets in strengths of 10mg, 15mg, 20mg, 30mg, 40mg, 60mg, and 80mg (NDA No. 020553) were voluntarily withdrawn for reaso	505(q)	2010-11-10	Denied	—
Lachman Consultant Services, Inc. - Citizen Petition FDA-2010-P-0526 · 14 docket documents Lachman Consultant Services, Inc. filed this citizen petition pursuant to 21 CFR 10.30 and 314.161, requesting that the FDA determine whether Oxycontin (oxycodone hydrochloride) Extended-release Tablets in strengths of 10 mg, 15 mg, 20 mg, 30 mg, 40 mg, 60 mg, 80 mg, and 160 mg (NDA 20-553) by Purdu	505(q)	2010-10-26	Denied	—
Troy and Alana Pack Foundation, et al - Citizen Petition FDA-2010-P-0393 · 8 docket documents The Troy and Alana Pack Foundation and affiliated organizations filed this citizen petition under 21 CFR 10.30 and 21 USC § 355 requesting that the FDA issue a public statement clarifying that there is insufficient clinical evidence to support claims that the reformulated OxyContin (controlled-relea	Other	2010-07-26	Denied	—
Lachman Consultant Services, Inc. - Citizen Petition FDA-2009-P-0203 · 5 docket documents Lachman Consultant Services, Inc., filed this citizen petition on behalf of an unnamed client pursuant to Section 505(j)(2)(C) of the Federal Food, Drug, and Cosmetic Act requesting that the FDA declare Oxycodone Hydrochloride and Acetaminophen Effervescent Tablets in strengths of 2.5 mg/500 mg, 5 m	Other	2009-05-01	Withdrawn	—
Vintage Pharmaceuticals - Citizen Petition FDA-2008-P-0598 · 6 docket documents Vintage Pharmaceuticals filed this suitability petition on November 14, 2008, pursuant to Section 505(j)(2)(C) of the Federal Food, Drug and Cosmetic Act, requesting that the FDA declare Oxycodone Hydrochloride Capsules, 5 mg suitable for submission under an Abbreviated New Drug Application, with th	Other	2008-12-02	Withdrawn	—
Patricia Gwen Kiser [Philip W. Thomas, P.A.] - Citizen Petition FDA-2008-P-0618 · 16 docket documents Patricia Gwen Kiser, through counsel Philip W. Thomas, P.A., filed this citizen petition requesting that the FDA revoke approval of the OxyContin label and compel Purdue Pharma to remove the misleading logarithmic scale graph from the package insert, disclose dysphoria as an adverse experience, and	505(q)	2008-12-02	Partially Denied	—
Citizen Petition from Purdue Pharma LP FDA-1999-P-2921 · 12 docket documents Purdue Pharma LP filed this citizen petition under Section 505 of the Federal Food, Drug, and Cosmetic Act requesting that the FDA declare the October 26, 1998 approval of Roxane Laboratories' NDA 20-932 for Roxicodone (oxycodone HCl) Sustained Release Tablets null and void, arguing that the applica	505(q)	2008-07-02	Granted	Purdue Pharma LP
Sheppard Mullin Richter & Hampton LLP - Citizen Petition FDA-2007-P-0352 · 4 docket documents On May 22, 2007, Sheppard Mullin Richter & Hampton LLP filed a citizen petition on behalf of Purdue Pharma LP requesting that the FDA determine that oxycodone hydrochloride extended release tablets in 15mg, 30mg, and 60mg strengths (NDA No. 020553) were voluntarily withdrawn for reasons other than s	505(q)	2008-06-10	Withdrawn	—

Source: Regulations.gov. FDA citizen petitions matched by application number.

Clinical Trials

282 trials from ClinicalTrials.gov — 5 recruiting, 3 active, 207 completed

Trial	Phase	Status	Sponsor	Enrollment	Dates
Multimodal Analgesia Effect on Post Surgical Patient NCT04240626	Phase 4	Active	University of California, Davis	60	2021-01-20 → 2026-06-24
Population Pharmacokinetics and Pharmacogenomics of Oral Oxycodone in Pediatric Surgical Patients NCT02044497	Phase 4	Active	Boston Children's Hospital	68	2014-05 → 2027-12
The Effect of General Anesthesia on Pharmacokinetics of Oxycodone in Pediatric NCT03054831	Phase 4	Active	Boston Children's Hospital	40	2019-07-08 → 2027-12
Oxycodone and Sufentanil for Analgesia in Hip Surgery NCT03685188	Phase 4	By Invitation	West China Hospital	570	2018-12-01 → 2025-07-31
Supracondylar Post-Operative Pain Study NCT03759028	Phase 4	Recruiting	University of California, Los Angeles	90	2019-02-26 → 2027-12-20
Opioid-Sparing and Pain-Reducing Properties of Syntocinon: A Dose-Effect Determination NCT04218409	Early Phase 1	Recruiting	University of Florida	45	2021-09-02 → 2026-12-31
Post-Op Pain Control for Prophylactic Intramedullary Nailing.NCT03823534	Phase 3	Recruiting	St. Louis University	60	2019-02-20 → 2027-03-31
Effects of an Opioid Free/Sparing Care Pathway for Patients Undergoing Obesity Surgery NCT03756961	N/A	Recruiting	Göteborg University	220	2019-05-01 → 2029-12-31
Ambulatory Gynecologic Surgery: Finding the Optimal Opioid Prescription NCT03588910	Phase 2	Completed	Montefiore Medical Center	120	2018-08-08 → 2019-08-04
Oxycodone Extended-release in the Treatment of Perioperative Pain in Patients Undergoing Orthopaedic Surgery NCT02238340	Phase 4	Completed	Hospital Central Dr. Luis Ortega	40	2012-03 → 2012-09

Source: ClinicalTrials.gov. Trials matched by ingredient name.

Drug Pricing (NADAC)

National Average Drug Acquisition Cost — Week of 2026-07-15 | 14 NDCs

Highest NADAC/Unit

$32.66

per ea

Lowest NADAC/Unit

$5.88

per ea

Brand NDCs

Generic NDCs

NDC Description	NADAC/Unit	Unit	Type	Generic NADAC	Effective
59011048010OXYCONTIN ER 80 MG TABLET	$32.66	EA	Brand	—	2026-06-17
59011048020OXYCONTIN ER 80 MG TABLET	$32.66	EA	Brand	—	2026-06-17
59011046020OXYCONTIN ER 60 MG TABLET	$26.55	EA	Brand	—	2026-06-17
59011046010OXYCONTIN ER 60 MG TABLET	$26.55	EA	Brand	—	2026-06-17
59011044020OXYCONTIN ER 40 MG TABLET	$18.77	EA	Brand	—	2026-06-17
59011044010OXYCONTIN ER 40 MG TABLET	$18.77	EA	Brand	—	2026-06-17

Showing 6 of 14 NDCs.

Source: NADAC (data.medicaid.gov). Prices reflect national average acquisition costs for retail community pharmacies.

VA Federal Supply Schedule

Government-negotiated contract prices | 28 NDCs (14 FSS, 14 Big4)

Lowest Price

$66.26

Highest Price

$2110.19

FSS NDCs

Big4 NDCs

Description	Price	Type	Vendor	Contract End
59011-0480-10OXYCONTIN 80MG TAB,CR	$2110.19	FSS	Purdue Pharma L.P.	04/30/2027
59011-0480-10OXYCONTIN 80MG TAB,CR	$2110.19	Big4	Purdue Pharma L.P.	04/30/2027
59011-0480-20OXYCONTIN 80MG TAB	$398.83	FSS	Purdue Pharma L.P.	04/30/2027
59011-0480-20OXYCONTIN 80MG TAB	$398.83	Big4	Purdue Pharma L.P.	04/30/2027
59011-0420-10OXYCONTIN 20MG TAB,CR	$704.87	FSS	Purdue Pharma L.P.	04/30/2027
59011-0420-10OXYCONTIN 20MG TAB,CR	$704.87	Big4	Purdue Pharma L.P.	04/30/2027

Showing 6 of 28 NDCs.

Source: VA Federal Supply Schedule (va.gov). Prices are government-negotiated contract prices.

Medicare Part D Spending

CMS annual spending data for Oxycontin (2024)

Total Spending

$337.8M

Total Claims

474,072

Beneficiaries

61,465

Avg Cost/Unit

$11.30

Spending Trend

$623.0M(2019)→$558.7M(2020)→$453.2M(2021)→$416.1M(2022)→$390.6M(2023)→$337.8M(2024)

YoY Change:-1.3%

5yr CAGR:+3.0%

Source: CMS Medicare Part D Spending by Drug (2024). Shows gross drug cost under Part D.

API Supply Chain6 active DMFs6 inactive

5 active API suppliers hold Drug Master Files for this ingredient.

SPECGX LLCOXYCODONE HYDROCHLORIDE USP (D)

DMF 69301987

NORAMCO LLCOXYCODONE HYDROCHLORIDE

DMF 163992003

VERANOVA LPOXYCODONE HYDROCHLORIDE

DMF 184722005

NORAMCO LLCOXYCODONE HYDROCHLORIDE DRUG SUBSTANCE

DMF 209752007

CHATTEM CHEMICALS INCOXYCODONE HYDROCHLORIDE, USP

DMF 234192010

SIEGFRIED USA LLCOXYCODONE HYDROCHLORIDE USP

DMF 235202010

MALLINCKRODT CHEMICAL INCInactiveOXYCODONE HYDROCHLORIDE PURIFIED RECRYSTALLIZED

DMF 28211977

NORAMCO INCInactiveOXYCODONE HYDROCHLORIDE

DMF 63181986

PENICK CORPInactiveOXYCODONE HYDROCHLORIDE

DMF 67681987

SIEGFRIED USA INCInactiveOXYCODONE HYDROCHLORIDE USP

DMF 193962006

JOHNSON MATTHEY PHARMACEUTICAL MATERIALSInactiveOXYCODONE HYDROCHLORIDE (MS PROCESS)

DMF 207292007

NORAMCO LLCInactiveOXYCODONE HYDROCHLORIDE USP (PROCESS II)

DMF 313772018

Source: FDA Drug Master Files (fda.gov). Type II API DMFs matched by ingredient.

Approval Letters

28 letters from Drugs@FDA

Date	Submission	Document
Jun 23, 2026	SUPPL -53	View Letter (PDF)
Dec 31, 2025	SUPPL -52	View Letter (PDF)
Nov 4, 2024	SUPPL -49	View Letter (PDF)
Dec 19, 2023	SUPPL -48	View Letter (PDF)
Oct 29, 2021	SUPPL -47	View Letter (PDF)
Mar 5, 2021	SUPPL -46	View Letter (PDF)
Nov 15, 2019	SUPPL -42	View Letter (PDF)
Oct 9, 2019	SUPPL -43	View Letter (PDF)
Oct 1, 2018	SUPPL -40	View Letter (PDF)
Oct 1, 2018	SUPPL -39	View Letter (PDF)
Oct 1, 2018	SUPPL -41	View Letter (PDF)
May 30, 2017	SUPPL -37	View Letter (PDF)
Dec 20, 2016	SUPPL -34	View Letter (PDF)
Oct 4, 2016	SUPPL -36	View Letter (PDF)
Aug 13, 2015	SUPPL -27	View Letter (PDF)
Jul 6, 2015	SUPPL -28	View Letter (PDF)
Oct 30, 2014	SUPPL -23	View Letter (PDF)
Aug 20, 2014	SUPPL -24	View Letter (PDF)
Apr 17, 2014	SUPPL -22	View Letter (PDF)
Apr 16, 2013	SUPPL -17	View Letter (PDF)
Apr 16, 2013	SUPPL -14	View Letter (PDF)
Jan 14, 2013	SUPPL -16	View Letter (PDF)
Jul 11, 2012	SUPPL -11	View Letter (PDF)
Jul 11, 2012	SUPPL -10	View Letter (PDF)
Oct 11, 2011	SUPPL -9	View Letter (PDF)
Nov 22, 2010	SUPPL -6	View Letter (PDF)
Jul 1, 2010	SUPPL -5	View Letter (PDF)
Apr 9, 2010	ORIG -1	View Letter (PDF)

Source: Drugs@FDA application documents.

Products (7)

Sort:

#001 — 10MG

RLD

15 patents0 exclusivities▴